New Cancer Drug Beats Chemotherapy in Study – The Wall Street Journal
Business News
- New Cancer Drug Beats Chemotherapy in Study The Wall Street Journal
- Esmo 2022 – double trouble for Lumakras Evaluate Pharma
- Sotorasib Significantly Improves Progression-Free Survival for KRAS G12C-Mutated Non-Small Cell Lung Cancer in Phase 3 Trial Pharmacy Times
- Data likely support approval of Amgen’s KRAS-targeted drug, but still come with disappointments STAT
- Amgen says Lumakras cuts risk of lung cancer progression by 34% Reuters
- View Full Coverage on Google News
Source: Business News